Phase 1 / Phase 2RecruitingINTERVENTIONAL
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
ClinicalTrials.gov · NCT06726577 · Registry updated: 2026-10-02
- Condition / research focus
- Amyotrophic Lateral Sclerosis
- Sponsor
- Talengen Institute of Life Sciences, Shenzhen, P.R. China.
- Countries with listed sites
- China
- Registry dates and results
- Start: 2026-06-04. Completion: 2027-04 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- TP04HN106 (drug)
- Saline (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Site recruitment: Recruiting